Bristol Myers Squibb (BMY) Short-term Investments (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Short-term Investments data on file, last reported at $912.0 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $912.0 million, up 0.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $912.0 million (up 0.55% YoY), and the FY2025 annual result was $464.0 million, down 9.55% from the prior year.
• Short-term Investments rose to $912.0 million in Q1 2026 per BMY's latest filing, from $464.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $2.6 billion in Q1 2022 and troughed at $130.0 million in Q4 2022.
• A 5-year average of $799.9 million and a median of $513.0 million in 2024 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments sank 95.65% in 2022, then surged 527.69% in 2023.
• A 5-year view of Short-term Investments shows it stood at $130.0 million in 2022, then surged by 527.69% to $816.0 million in 2023, then plunged by 37.13% to $513.0 million in 2024, then retreated by 9.55% to $464.0 million in 2025, then soared by 96.55% to $912.0 million in 2026.
• Business Quant data shows BMY's Short-term Investments at $912.0 million in Q1 2026, $464.0 million in Q4 2025, and $776.0 million in Q3 2025.